Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases

DISEASE CHARACTERISTICS:

• Histologically confirmed invasive breast cancer

• Stage IV disease

• At least 1 measurable CNS lesion ≥ 10 mm on T1-weighted gadolinium-enhanced MRI

• No single brain metastasis that could be treated by surgery

• HER-2 positive primary tumor as defined as IHC3+ or IHC2+ and FISH-positive

• Hormone receptor status: not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

• Life expectancy ≥ 3 months

• Absolute Neutrophil Count (ANC) ≥ 1,000/mm^3

• Platelet count ≥ 100,000/mm^3

• Hemoglobin ≥ 10g/dL

• Creatinine ≥ 1.5 times upper limit of normal (ULN)

• Albumin ≥ 2.5 g/dL

• Serum bilirubin ≤ 1.5 times ULN (unless due to Gilbert's syndrome)

• ASAT and ALAT ≤ 3 times ULN (≤ 5 times ULN with documented liver metastasis)

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception 2 weeks before, during, and for 28 days after completion of study treatment (female) or for 1 week after completion of treatment (male)

• Able to swallow and retain oral medication

• Affiliated to a Social Security System

• No known contraindication to MRI

• No prior or active malignancy, unless disease free for ≥ 10 years

• No other concurrent severe and/or uncontrolled medical disease which could compromise study participation, including any of the following:

• Infection

• Cardiac disease (e.g., uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within the past year, Left Ventricular EJection Fraction (LVEF) > grade 2)

• Current active hepatic or biliary disease (except for Gilbert syndrome, asymptomatic gallstones, liver metastasis or stable chronic liver disease per investigator assessment)

• Renal disease

• Active gastrointestinal (GI) tract ulceration, malabsorption syndrome, active uncontrolled ulcerative colitis, or disease significantly affecting GI function

• Severely impaired lung function (e.g., spirometry and diffusion capacity of lung for carbon monoxide (DLCO) ≤ 50% of normal, and O_2 saturation ≤ 88% at rest on room air)

• No known dihydropyrimidine dehydrogenase deficiency

• No significantly altered mental status prohibiting the understanding of the study, or with psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

• Not deprived of liberty or placed under the authority of a tutor

PRIOR CONCURRENT THERAPY:

• At least 2 weeks since prior breast cancer treatment (e.g., trastuzumab, chemotherapy, immunotherapy or biological response modifiers, endocrine therapy, or radiotherapy)

• More than 30 days since prior investigational drugs

• More than 14 days since prior and no concurrent strong inhibitors or inducers of the cytochrome P450 isoenzyme 3A4 (CYP3A4) (i.e., clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir)

• No prior whole brain radiotherapy (WBRT) or brain stereotactic radiotherapy

• No prior treatment with capecitabine and/or lapatinib ditosylate

• No prior resection of the stomach or small bowel

• No concurrent systemic treatment or radiation therapy for breast cancer (except corticosteroid, bisphosphonates, or mannitol)